This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Chong Kun Dang Pharmaceutical Corporation. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Sera Lee - Innovator in CETP Inhibition
Introduction
Sera Lee is a notable inventor based in Yongin, South Korea. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit CETP activity. Her work aims to improve cholesterol levels in patients, showcasing her commitment to advancing healthcare.
Latest Patents
Sera Lee holds a patent for "Cycloalkenyl aryl derivatives for CETP inhibitor." This invention relates to cycloalkenyl aryl derivatives, their isomers, pharmaceutically acceptable salts, hydrates, or solvates. The patent also includes a method for preparing these derivatives and pharmaceutical compositions containing them. The compounds developed show the potential to increase HDL-cholesterol and decrease LDL-cholesterol, which is crucial for cardiovascular health.
Career Highlights
Sera Lee is currently employed at Chong Kun Dang Pharmaceutical Corporation, where she continues to innovate in the pharmaceutical industry. Her work has led to advancements in treatments that can significantly impact patient health and well-being.
Collaborations
Sera collaborates with talented coworkers, including Jung Taek Oh and SeoHee Lee. These partnerships enhance her research and development efforts, contributing to the success of her projects.
Conclusion
Sera Lee's contributions to the field of CETP inhibition through her innovative patent demonstrate her dedication to improving healthcare solutions. Her work at Chong Kun Dang Pharmaceutical Corporation highlights her role as a key player in the pharmaceutical industry.